Evogliptin

Drug Profile

Evogliptin

Alternative Names: DA-1229; SUGANON; Sugarnon

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; GEROPHARM; Luye Pharma Group; Tobira Therapeutics
  • Class Amides; Antihyperglycaemics; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 12 Sep 2016 Phase-I clinical trials in Non-alcoholic steatohepatitis (Combination therapy, in volunteers) in USA (unspecified route)
  • 01 Sep 2016 Preclinical trials in Type-2 diabetes mellitus (Combination therapy) in Russia (PO) before August 2016 (GEROPHARM pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top